Antonio Jimenez Jimenez, MD, discusses the ACCESS trial of PTCy-based GVHD prophylaxis after mismatched unrelated donor stem cell transplantation.

Just when we thought we had enough on our medical to-do list-Pap smears, mammograms, cholesterol checks, stress management, ...

New drugs that target "zombie" tuberculosis (TB) cells are now a step closer, thanks to a new study led by the University of ...

In a recent study, Associate Professor Makoto Ikeya (Department of Clinical Application) and his team of researchers ...

Anti-CD20 therapies, a type of MS treatment, changes levels and profiles of several immune cells in people with MS, a study ...

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...

Alzheimer's disease (AD) is a common, debilitating neurodegenerative disease affecting about 10% of people over the age of 65 ...

A war weapon used in World War One went on to become a key component in treating blood cancer with chemotherapy ...

Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes ...

A similarly gloomy simulation posted by Dr Paulien Moyaert back in May documented how being diagnosed with cancer can lead to ...

Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.

The goal is to test whether the chip can give people who are paralyzed the ability to use their mind to control electronic ...